AMY MCDONALD: Open Payments
NPI 1245980911 · FRANKLIN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$354 in 19 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $18 · 2025 $354
Food & beverage: $354
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $62 |
| Novo Nordisk Inc | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Dexcom, Inc. | 1 | $30 |
| Merck Sharp & Dohme LLC | 2 | $29 |
| GlaxoSmithKline, LLC. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
Products named: VRAYLAR, NEXLETOL, Dexcom G6 Transmitter, AREXVY, Veozah, REXULTI, Rybelsus, LEQVIO.
Industry payments across IN — which companies pay providers there.
